METHOD FOR ESTIMATING SKIN MELANOMA NEOADJUVANT TREATMENT EFFECTIVENESS Russian patent published in 2008 - IPC A61B10/00 G01N33/52 

FIELD: medicine.

SUBSTANCE: method involves carrying out immunohistochemical examination when applying neoadjuvant treatment, in particular, paratumoral chemotherapy on Autoplasma combined with radiation therapy. When examining treatment results with immunohistochemical methods, melanoma marker Melan PNL2 expression is determined. Non-uniform or moderately marked melanoma marker Melan PNL2 expression being found unchanged with cytospecific melanocyte Melan PNL2 antigen being retained, reaction with apoptosis factor p53, with antibodies bcl-2, with proliferation factor Ki-67 marker and with antibodies CD95 is recorded. If no reaction with apoptosis factor p53 and reaction with antibodies bcl-2 being observed or weak positive antigen staining, low proliferative melanocyte activity, proliferation block as Ki-67 protein localization injury and apoptosis activation in reaction with antibodies CD95 being available, the treatment is estimated as effective, pointing out to tumor pathomorphosis.

EFFECT: wide range of diagnostic applications.

5 dwg